Page last updated: 2024-11-04

sulfamethoxazole and Tuberculosis, Multidrug-Resistant

sulfamethoxazole has been researched along with Tuberculosis, Multidrug-Resistant in 2 studies

Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.

Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Research Excerpts

ExcerptRelevanceReference
" However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients."5.43Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016)
" However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients."1.43Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alsaad, N1
Dijkstra, JA1
Akkerman, OW1
de Lange, WC1
van Soolingen, D1
Kosterink, JG1
van der Werf, TS1
Alffenaar, JW1
Vilchèze, C1
Jacobs, WR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis[NCT01832987]Phase 212 participants (Actual)Interventional2013-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

2 other studies available for sulfamethoxazole and Tuberculosis, Multidrug-Resistant

ArticleYear
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:7

    Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tes

2016
The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:10

    Topics: Anaerobiosis; Anti-Bacterial Agents; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculo

2012